Tyra Biosciences, Inc. is a clinical-stage biotechnology company dedicated to creating next-generation precision medicines for oncology and genetically defined conditions by modulating fibroblast growth factor receptor (FGFR) signaling. The company’s core technology is the SNÅP platform, which integrates rapid protein crystallography, cell-based assays, and in vivo models to generate molecular snapshots that guide the design of small molecule inhibitors with high potency, selectivity and tolerability. Using this approach, Tyra Biosciences has built a wholly owned pipeline of oral drug candidates focused on targets historically viewed as difficult to drug. Its lead asset, oral dabogratinib (formerly TYRA-300), is a FGFR3-selective inhibitor engineered to spare FGFR1, FGFR2 and FGFR4 activity, thereby aiming to reduce the class‑related toxicities of earlier pan‑FGFR agents. Dabogratinib is currently advancing in three Phase 2 trials: SURF303 for low‑grade upper tract urothelial carcinoma, SURF302 for intermediate‑risk non‑muscle invasive bladder cancer, and BEACH301 for achondroplasia in children. Beyond the FGFR3 program, the company is evaluating TYRA‑430, an FGFR4/3‑biased molecule, in a Phase 1 study for FGF19‑driven hepatocellular carcinoma, and TYRA‑200, a pan‑FGFR1/2/3 inhibitor designed to overcome acquired resistance, in a Phase 1 trial for FGFR2‑mutant cholangiocarcinoma. All programs are internally discovered and the company retains full development and commercialization rights to each candidate.

Tyra Biosciences, Inc. does not yet generate product revenue, as its candidates remain in clinical development and no therapy has received regulatory approval. The company finances its operations through a combination of private equity placements, public offerings and grant funding, which support preclinical research, clinical trial execution and infrastructure building. Looking forward, Tyra Biosciences intends to monetize its pipeline by securing marketing approval for its product candidates and then commercializing the approved therapies either independently or through strategic partnerships with larger biopharmaceutical firms. The company has stated that it will retain development and commercial rights for indications and geographies where it believes it can successfully bring products to market on its own, while remaining open to collaborations that provide access to additional resources or specialized expertise. Revenue will therefore depend on the timing and success of clinical milestones, the ability to obtain pricing and reimbursement from payers, and the scope of any commercialization arrangements that are ultimately put in place.

Tyra Biosciences, Inc. operates in a competitive field that includes several approved FGFR‑targeted therapies and numerous disease‑specific treatments. Direct competitors in the FGFR space comprise erdafitinib (approved for urothelial carcinoma), pemigatinib, futigatinib and the withdrawn infigratinib (all approved or previously approved for cholangiocarcinoma), as well as investigational agents from other companies that aim to inhibit FGFR isoforms with varying selectivity profiles. In the urothelial cancer arena, the only currently marketed product for low‑grade upper tract urothelial carcinoma is Jelmyto, a mitomycin‑C hydrogel, while intermediate‑risk non‑muscle invasive bladder cancer is served by Zusduri, another mitomycin‑C hydrogel, and the off‑label use of bacillus Calmette‑Guérin chemotherapy. For achondroplasia, the approved therapies are Voxzogo, a daily C‑natriuretic peptide analog, and Yuviwel, a weekly trans‑conjugated C‑natriuretic peptide prodrug, with additional candidates such as infigratinib under study. Tyra Biosciences differentiates itself through its SNÅP platform, which enables rapid iteration of chemical structures to achieve greater than ten‑fold selectivity for FGFR3 over FGFR1 and FGFR2, a feature that aims to limit off‑target toxicities like hyperphosphatemia, skin nail changes and hepatic enzyme elevations observed with less selective inhibitors. The company also focuses on overcoming resistance mutations, a strategy intended to prolong responses in tumors that develop pathway bypass mechanisms, thereby addressing a key limitation of existing FGFR‑directed treatments.

Tyra Biosciences, Inc. anticipates serving patients with specific oncology and rare genetic disorders whose disease is driven by FGFR alterations. In urothelial carcinoma, the target populations include individuals with low‑grade upper tract urothelial carcinoma and those with intermediate‑risk non‑muscle invasive bladder cancer, both of which represent subsets of bladder cancer patients characterized by low grade and limited invasiveness. In the skeletal dysplasia space, the company’s initial focus is on children with achondroplasia, the most common form of disproportionate short stature, with plans to explore other FGFR3‑mediated conditions such as hypochondroplasia and related skeletal disorders. Beyond these primary indications, Tyra Biosciences expects to treat adults with FGF19‑positive hepatocellular carcinoma and patients with FGFR2‑resistant cholangiocarcinoma, addressing unmet needs in liver cancer and bile‑duct malignancies. The company’s therapies will be prescribed by specialists such as oncologists, urologists, hepatologists, gastroenterologists, geneticists and pediatricians, and will be administered in settings ranging from academic medical centers and community hospitals to outpatient infusion clinics and specialty care facilities.